Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-45

• The guidance for treating Mis-c was this
• Biological: Remestemcel-L
  Participants may receive up to 2 infusions of 2 x 10^6 remestemcel-L within a 5-day period.
  
  The guidance for treating Covid-19 was this.
  Group 1: 2x10^6 MSC/kg of body weight plus standard of care, administered twice during the first week, with the second infusion at 4 days following the first infusion (± 1 day)

We have new news, that the Mis-c patients were dosed twice in 48 hours and NOW they are saying this should be the standard moving forward for other acute inflammatory conditions.

So - I have been saying for sometime that we could soon be running another Covid Ards trial in addition to an all cause Ards trial.

Is this a new sweet spot for Ards?

Geez those secondary endpoints could be worth their wait in gold.

Reg

Tic Tic Tic Tiiiiiiiiiiiiiiiicccccccc